Prehospital Tranexamic Acid Use for Traumatic Brain Injury: TXA Study
The Resuscitation Outcome Consortium’s (ROC) TXA Study is a phase II multi-site, randomized double-blind placebo controlled trial. This study looks at individuals with life threatening or life altering traumatic brain injury, to assess if they do better when they receive a drug known as Tranexamic Acid, in order to stabilize their bleeding compared to when they do not receive the drug in a prehospital setting.
This study will be conducted in 10 participating ROC sites across the United States and Canada with a total expected enrollment of 963 patients. The study is funded by the United States Department of Defense, the National Institute of Health, Defense Research and Development Canada, and the Heart and Stroke Foundation of Canada. The participating Emergency Paramedic Services from the Toronto Regional RescuNet are Toronto Paramedic Services and Air Ornge.
The Toronto site ROC Principal Investigator for the study is Dr. Laurie Morrison, St. Michael’s Hospital; the study site investigators are Dr. Sandro Rizoli (St. Michael’s) and Dr. Barto Nascimento (Sunnybrook).
Update – Jan 25, 2017: ROC TXA study has enrolled 55 patients for the Toronto Site and 882 patients across all ROC sites.
Below are the most recent enrollment numbers for Toronto:
|Toronto Paramedic Services||Ornge|
|St. Michael's Hospital||7||10|